Date: September 23, 2022  Administrative Circular: 2022:38

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 4 – Biological Products & Appendix E – Management of Biologicals

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

- Pfizer vaccine (3 mcg) has been added to the pediatric population (6 months – 4 years of age) section. Moderna vaccine (25 mcg) is preferred for this population.
- Minimum interval content has been added to footnote B.

Please remove page numbers: 1-3 dated September 14, 2022
Please add new page numbers: 1-3 dated September 23, 2022

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) 5-11 years of age (Orange Vial Cap)

Title of this page has been changed from 'pediatric presentation' to '5-11 years of age presentation' to help differentiate it from the Pfizer-BioNTech vaccine for children 6 months to 4 years of age.

Please remove page numbers: 1-5 dated September 8, 2022
Please add new page numbers: 1-5 dated September 23, 2022

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) 6 months to 4 years of age (Maroon Vial Cap)

- A new biological product page has been developed for COMIRNATY® (Pfizer-BioNTech) 6 months to 4 years of age.
- This vaccine is supplied with a maroon vial cap and maroon label border.
- This vaccine is provided as a 3 dose primary series with 8 weeks between doses.
- This product will only be available by special request.

Please add new page numbers: 1-5 dated September 23, 2022
Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated September 2022, and replace with the enclosed updated Title Page and Table of Contents dated September 23, 2022.

The COVID-19 mRNA Vaccine Comparison Table has been updated. The updated resource will be posted on the COVID-19 vaccination toolkit for health professionals under General COVID-19 vaccine information.

Appendix E – Management of Biologicals

Guidance for Receiving and Handling the Pfizer-BioNTech COVID-19 mRNA Vaccine (including dry ice procedures)

Content for the vaccine presentation for those 6 months – 4 years of age has been added under “Temperature Requirements for Shipping and Storage upon Receipt of the Vaccine”.

Please remove page numbers: 1-13 dated July 29 & August 26, 2022
Please add new page numbers: 1-13 dated September 23, 2022
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease,
Population and Public Health Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division